These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

603 related articles for article (PubMed ID: 23092874)

  • 21. Predictive and prognostic significance of p27, Akt, PTEN and PI3K expression in HER2-positive metastatic breast cancer.
    Okutur K; Bassulu N; Dalar L; Aydin K; Bozkurt M; Pilanci KN; Dogusoy GB; Tecimer C; Mandel NM; Demir G
    Asian Pac J Cancer Prev; 2015; 16(7):2645-51. PubMed ID: 25854340
    [TBL] [Abstract][Full Text] [Related]  

  • 22. PI3K-p110α mediates resistance to HER2-targeted therapy in HER2+, PTEN-deficient breast cancers.
    Wang Q; Liu P; Spangle JM; Von T; Roberts TM; Lin NU; Krop IE; Winer EP; Zhao JJ
    Oncogene; 2016 Jul; 35(27):3607-12. PubMed ID: 26500061
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Alterations of the genes involved in the PI3K and estrogen-receptor pathways influence outcome in human epidermal growth factor receptor 2-positive and hormone receptor-positive breast cancer patients treated with trastuzumab-containing neoadjuvant chemotherapy.
    Takada M; Higuchi T; Tozuka K; Takei H; Haruta M; Watanabe J; Kasai F; Inoue K; Kurosumi M; Miyazaki M; Sato-Otsubo A; Ogawa S; Kaneko Y
    BMC Cancer; 2013 May; 13():241. PubMed ID: 23679233
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Association between gain-of-function mutations in PIK3CA and resistance to HER2-targeted agents in HER2-amplified breast cancer cell lines.
    Kataoka Y; Mukohara T; Shimada H; Saijo N; Hirai M; Minami H
    Ann Oncol; 2010 Feb; 21(2):255-262. PubMed ID: 19633047
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pathologic complete response after preoperative anti-HER2 therapy correlates with alterations in PTEN, FOXO, phosphorylated Stat5, and autophagy protein signaling.
    Holmes FA; Espina V; Liotta LA; Nagarwala YM; Danso M; McIntyre KJ; Osborne CR; Anderson T; Krekow L; Blum JL; Pippen J; Florance A; Mahoney J; O'Shaughnessy JA
    BMC Res Notes; 2013 Dec; 6():507. PubMed ID: 24304724
    [TBL] [Abstract][Full Text] [Related]  

  • 26. An integrative analysis of PIK3CA mutation, PTEN, and INPP4B expression in terms of trastuzumab efficacy in HER2-positive breast cancer.
    Sueta A; Yamamoto Y; Yamamoto-Ibusuki M; Hayashi M; Takeshita T; Yamamoto S; Iwase H
    PLoS One; 2014; 9(12):e116054. PubMed ID: 25542038
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Src, a potential target for overcoming trastuzumab resistance in HER2-positive breast carcinoma.
    Peiró G; Ortiz-Martínez F; Gallardo A; Pérez-Balaguer A; Sánchez-Payá J; Ponce JJ; Tibau A; López-Vilaro L; Escuin D; Adrover E; Barnadas A; Lerma E
    Br J Cancer; 2014 Aug; 111(4):689-95. PubMed ID: 24937674
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sensitivity to targeted therapy differs between HER2-amplified breast cancer cells harboring kinase and helical domain mutations in PIK3CA.
    Garay JP; Smith R; Devlin K; Hollern DP; Liby T; Liu M; Boddapati S; Watson SS; Esch A; Zheng T; Thompson W; Babcock D; Kwon S; Chin K; Heiser L; Gray JW; Korkola JE
    Breast Cancer Res; 2021 Aug; 23(1):81. PubMed ID: 34344439
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Correlation between activation of PI3K/AKT/mTOR pathway and prognosis of breast cancer in Chinese women.
    Deng L; Chen J; Zhong XR; Luo T; Wang YP; Huang HF; Yin LJ; Qiu Y; Bu H; Lv Q; Zheng H
    PLoS One; 2015; 10(3):e0120511. PubMed ID: 25816324
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Development of the CK-MB-1 trastuzumab-resistant HER2-positive breast cancer cell line and xenograft animal models.
    Chung WP; Huang WL; Liao WA; Huang WL; Liu YY; Su WC
    Cancer Med; 2021 Apr; 10(7):2370-2379. PubMed ID: 33665980
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Preclinical modeling of combined phosphatidylinositol-3-kinase inhibition with endocrine therapy for estrogen receptor-positive breast cancer.
    Sanchez CG; Ma CX; Crowder RJ; Guintoli T; Phommaly C; Gao F; Lin L; Ellis MJ
    Breast Cancer Res; 2011 Mar; 13(2):R21. PubMed ID: 21362200
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Direct inhibition of PI3K in combination with dual HER2 inhibitors is required for optimal antitumor activity in HER2+ breast cancer cells.
    Rexer BN; Chanthaphaychith S; Dahlman K; Arteaga CL
    Breast Cancer Res; 2014 Jan; 16(1):R9. PubMed ID: 24451154
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical significance of PTEN and p-Akt co-expression in HER2-positive metastatic breast cancer patients treated with trastuzumab-based therapies.
    Fabi A; Metro G; Di Benedetto A; Nisticò C; Vici P; Melucci E; Antoniani B; Perracchio L; Sperduti I; Milella M; Cognetti F; Mottolese M
    Oncology; 2010; 78(2):141-9. PubMed ID: 20389136
    [TBL] [Abstract][Full Text] [Related]  

  • 34. PI3KCA mutations and/or PTEN loss in Her2-positive breast carcinomas treated with trastuzumab are not related to resistance to anti-Her2 therapy.
    Barbareschi M; Cuorvo LV; Girlando S; Bragantini E; Eccher C; Leonardi E; Ferro A; Caldara A; Triolo R; Cantaloni C; Decarli N; Galligioni E; Dalla Palma P
    Virchows Arch; 2012 Aug; 461(2):129-39. PubMed ID: 22744290
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A combinatorial biomarker predicts pathologic complete response to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2+ breast cancer.
    Veeraraghavan J; De Angelis C; Mao R; Wang T; Herrera S; Pavlick AC; Contreras A; Nuciforo P; Mayer IA; Forero A; Nanda R; Goetz MP; Chang JC; Wolff AC; Krop IE; Fuqua SAW; Prat A; Hilsenbeck SG; Weigelt B; Reis-Filho JS; Gutierrez C; Osborne CK; Rimawi MF; Schiff R
    Ann Oncol; 2019 Jun; 30(6):927-933. PubMed ID: 30903140
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comprehensive genomic profiling of ESR1, PIK3CA, AKT1, and PTEN in HR(+)HER2(-) metastatic breast cancer: prevalence along treatment course and predictive value for endocrine therapy resistance in real-world practice.
    Bhave MA; Quintanilha JCF; Tukachinsky H; Li G; Scott T; Ross JS; Pasquina L; Huang RSP; McArthur H; Levy MA; Graf RP; Kalinsky K
    Breast Cancer Res Treat; 2024 Oct; 207(3):599-609. PubMed ID: 38872062
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Activated phosphoinositide 3-kinase/AKT signaling confers resistance to trastuzumab but not lapatinib.
    O'Brien NA; Browne BC; Chow L; Wang Y; Ginther C; Arboleda J; Duffy MJ; Crown J; O'Donovan N; Slamon DJ
    Mol Cancer Ther; 2010 Jun; 9(6):1489-502. PubMed ID: 20501798
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical significance of p95HER2 overexpression, PTEN loss and PI3K expression in p185HER2-positive metastatic breast cancer patients treated with trastuzumab-based therapies.
    Tural D; Serdengecti S; Demirelli F; Öztürk T; İlvan S; Turna H; Özgüroglu M; Büyükünal E
    Br J Cancer; 2014 Apr; 110(8):1968-76. PubMed ID: 24595002
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Targeting PI3K/mTOR overcomes resistance to HER2-targeted therapy independent of feedback activation of AKT.
    O'Brien NA; McDonald K; Tong L; von Euw E; Kalous O; Conklin D; Hurvitz SA; di Tomaso E; Schnell C; Linnartz R; Finn RS; Hirawat S; Slamon DJ
    Clin Cancer Res; 2014 Jul; 20(13):3507-20. PubMed ID: 24879796
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer.
    Berns K; Horlings HM; Hennessy BT; Madiredjo M; Hijmans EM; Beelen K; Linn SC; Gonzalez-Angulo AM; Stemke-Hale K; Hauptmann M; Beijersbergen RL; Mills GB; van de Vijver MJ; Bernards R
    Cancer Cell; 2007 Oct; 12(4):395-402. PubMed ID: 17936563
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 31.